Biomm was born with the mission of developing, manufacturing and commercializing biomedicines with global competitiveness, quality and accessibility, bringing the best treatments to a growing number of people.
Founded in 2001, during a split-up process of a major global insulin manufacturer, Biomm is the first and only brazilian company totally focused in biotechnology.
Our production site is located in Nova Lima, in the metropolitan area of Belo Horizonte (MG), and is fully equipped with state-of-art biomedicine manufacturing technology. The plant was built with the objective of providing Brazil with productive independence with regards to high technology biomedicines, such as insulin analogues.
Our technology team is a pioneer in pharmaceutical biotechnology in Brazil and very experienced, adding up to more than 20 patients registered around the world in the last two decades. The team is supported by an also very experienced executive team, which is always well connected to the trends and future perspectives of the market.
Researchers and entrepreneurs found Biobrás to produce, initially, enzymes extracted from animal and plant sources. Targeted for the pharmaceutical industry, some of the enzymes were: pepsin, bromelain, papain, trypsin, chymotrypsin and cellulase complexes.
BRAZILIAN PIONEERING IN INSULIN MANUFACTURING
Biobrás and Eli Lilly & Co (USA) form a joint venture for the production of insulins in Brazil. Insulin crystals are produced in Montes Claros (MG) and commercialized aroung the world. Biobrás facilities are inspected and approved by US FDA (Food and Drug Administration).
INJECTABLE INSULIN MANUFACTURING
After establishing partnership with Eli Lilly & Co, Biobrás starts to develop highly purified insulins in injectable formulation, meaning that the company can offer ready-to-use insulin.
Biobrás and the University of Brasilia establish a partnership to develop the industrialization of the production process of recombinant proteins, such as insulins.
PRODUCTION AND FORMULATION OF HIGHLY PURIFIED INSULINS
Biobrás becomes world’s 4th largest insulin producer, exporting its products to more than 20 countries.
RECOMBINANT HUMAN INSULIN PATENT
USPTO (United States Patent and Trademark Office) grants recombinant human insulin patent to Biobrás, with property and exclusive use rights.
We are a result of Biobrás’ spin off process, after it was acquired by danish multinational Novo Nordisk, in 2001. Biomm inherited all the accumulated knowledge of 26 years in the biopharmaceutical industry and kept all intellectual property patents, researchers and equipment related to the develop of our insulin production process.
STOCK MARKET LISTING
Biomm’s stocks start to be negotiated in Bovespa, the stock exchange market of São Paulo.
Biomm signed exclusive partnership deals with 2 international pharmaceutical companies: Gan & Lee (China) and Bioton (Poland), for the commercialization of products for Diabetes.
Biomm announced R$ 330 M investment in the construction of a manufacturing site in Nova Lima (MG), in a 100.000 m² piece of land, with 12.000 m² of built area and annual manufacturing capacity of 20 million vials of insulins and insulin analogues.
SITE INAUGURATION AND NEW GLOBAL PARTNERSHIPS
Nova Lima’s manufacturing site is inaugurated e two new exclusivity partnership deals are signed: with american company MannKind Corp, for the commercialization of inhalable insulin, and with south korean company Celltrion healthcare, for the commercialization of oncology treatments.
1st PRODUCT REGISTRATION APPROVAL BY ANVISA
ANVISA approves Glargilin (insulin glargine), a long-acting insulin analogue.
ANVISA approves Herzuma (trastuzumab) and Afrezza (insulina humana em pó para inalação)
Biomm expands portfolio with the commercialization of Wosulin (human insulin) and with the regulatory approval of Ghemaxan (Enoxaparin sodium)